$4D Molecular Therapeutics (FDMT.US)$
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
Saturday, 8th February at 2:30 pm
• 3E10 vg/eye achieved an 83% reduction in injection burden vs. projected on-label aflibercept 2 mg Q8W, 70% required 0-1 supplemental injection, and 57% were injection-free through 52 weeks
• In the recently diagnosed subgroup, which most resembles the...